DetermaRx™ is a treatment stratification test to identify patients with stage I and IIA non-squamous NSCLC who may benefit from adjuvant chemotherapy.
patients are diagnosed with early-stage non-small cell lung cancer (NSCLC) each year.2
of early-stage patients will not survive despite complete surgical resection.3
DetermaRx provides a
to understand which patients may benefit from chemotherapy.
Now paired from the same tissue sample, DetermaRx + EGFR™ is the complete molecular testing solution in early-stage NSCLC, guiding treatment selection and sequencing of targeted therapy (osimertinib) and adjuvant chemotherapy.
Here’s How DetermaRx Works
Identify your patients who may benefit from chemotherapy
Order DetermaRx for your patient with stage I or IIA non-squamous NSCLC undergoing resection. You may also opt in for EGFR mutation analysis on the same tissue sample if you wish.
We analyze the molecular signature of your patient’s tumor tissue to stratify your patient’s risk.
- DetermaRx is a 14-gene molecular stratification test that has been validated in two independent cohorts with close to 1400 patients.4
- DetermaRx outperformed NCCN criteria in identifying patients at high risk for mortality from stage IA, IB, and IIA non-squamous NSCLC.4
- Patients identified by DetermaRx as high-risk* and who were treated with adjuvant platinum chemotherapy had 91.7% 5-year disease-free survival compared to 48.9% 5-year DFS for high-risk patients who did not receive chemotherapy.1
- Significant difference in survival amongst chemotherapy treated vs. untreated high-risk* patients was reinforced in an expanded 250 patient prospective cohort, in which majority of patients were stage IA.5
- DetermaRx identified high-risk patients who responded to adjuvant chemotherapy, independent of EGFR status.5
*Test identified intermediate- and high-risk patients were grouped together in this analysis and designated as molecular high-risk.
“The integration of testing for targeted therapy, including EGFR mutation status and chemotherapy selection by DetermaRx on the same sample, will enable oncologists to optimize and sequence treatment post-surgery. In my opinion, these two tests together close the few remaining gaps that we currently face in deciding adjuvant therapy for early-stage adenocarcinoma of the lung. With these results, I would feel confident initiating chemotherapy, followed by targeted therapy for the EGFR-positive, DetermaRx high-risk patients I see in my practice.”
We are committed to providing accessible, affordable testing for all
Insurance and Eligibility
We accept all insurance on an out-of-network basis. We will contact you if your estimated out-of-pocket cost exceeds $100.
1. Woodard, et al. (2018) Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer. Clinical Lung Cancer 19:58.
2. SEER data.
3. Chansky, et al. (2017) The IASLC Lung Cancer Staging Project: External validation of the revision of the TNM stage groupings in the eight edition of the TNM classification of lung cancer. J Thorac Oncol 12:1109
4. Kratz, et al. (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international studies. Lancet 379:823.
5. Woodard, et al. (2020) Molecular risk stratification is independent of EGFR mutation status in identifying early stage non-squamous non-small cell lung cancer patients at risk for recurrence and likely to benefit from adjuvant chemotherapy. Abstract presented at 2020 North America Conference on Lung Cancer.